Trial Outcomes & Findings for Topical Antibiotics and Intravitreous Injections (NCT NCT00410891)

Last Updated: 2017-11-06

Results Overview

The percentage of patients with a positive bacterial culture following administration of study treatment is presented.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

129 participants

Primary outcome timeframe

Study day 1, assessed following administration of study treatment

Results posted on

2017-11-06

Participant milestones
Measure	Topical Antibiotic topical gatifloxacin 4 times per day gatifloxacin
Overall Study STARTED	129
Overall Study COMPLETED	129
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Topical Antibiotics and Intravitreous Injections

Baseline characteristics by cohort
Measure	Topical Antibiotic n=129 Participants topical gatifloxacin 4 times per day gatifloxacin
Age, Continuous	77 years STANDARD_DEVIATION 13 • n=93 Participants
Sex: Female, Male Female	81 Participants n=93 Participants
Sex: Female, Male Male	48 Participants n=93 Participants
Conjunctival Bacterial Flora Coagulase-negative staphylococcus	75 percentage of patients n=93 Participants
Conjunctival Bacterial Flora Staphylococcus aureus	7 percentage of patients n=93 Participants
Conjunctival Bacterial Flora Gram-negative rods	6 percentage of patients n=93 Participants
Conjunctival Bacterial Flora Streptococcus species	7 percentage of patients n=93 Participants

Timeframe: Study day 1, assessed following administration of study treatment

The percentage of patients with a positive bacterial culture following administration of study treatment is presented.

Outcome measures
Measure	Topical Antibiotic n=129 Participants topical gatifloxacin 4 times per day gatifloxacin
Positive Culture	8 percentage of patients

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Stanford

Phone: 6504984791